Literature DB >> 27888395

Utility of FVC/DLCO ratio to stratify the risk of mortality in unselected subjects with pulmonary hypertension.

Lacedonia Donato1, Carpagnano Giovanna Elisiana1, Galgano Giuseppe2, Schino Pietro2, Correale Michele3, Natale Daniele Brunetti4, Ventura Valentina2, Di Biase Matteo3, Foschino Barbaro Maria Pia3.   

Abstract

In patients with systemic sclerosis, a ratio between forced vital capacity (FVC) and diffusing capacity of carbon monoxide (DLCO, FCV%/DLCO%) >1.5 might be a predictor of pulmonary hypertension (PH). The aim of this study is, therefore, to evaluate whether this index can be used in patients with PH, regardless of etiology. 83 consecutive outpatients with suspected PH at non-invasive work-up underwent spirometry and DLCO test before right heart catheterization (RHC); FVC%/DLCO% ratio was then calculated and compared with mean pulmonary-artery-pressure (mPAP) and mortality at 5-year follow-up. Significant correlations between FVC%/DLCO% and PAsP and mPAP levels were found (p < 0.05). After ROC curve analysis and definition of best cut-off values for PAsP and FVC%/DLCO%, increased mPAP values at RHC were observed comparing subjects with both PAsP and FVC%/DLCO% values below cut off values (-/-), either PAsP or FVC%/DLCO% above cut off values (±), or both above (+/+) (p < 0.05). Poorer survival rates are observed at follow-up with higher FVC%/DLCO% values (0% for <1, 17.4% for 1-3, 33.3% for >3, p < 0.05), when comparing subjects with either increased PAsP and FVC%/DLCO% values or both with those with lower (log-rank p < 0.05). Even in subjects with mPAP at RHC >25 mmHg, increased FVC%/DLCO% values predicted a worse outcome (p < 0.05). FVC%/DLCO% values are related to mPAP in subjects with suspected PH, and may further stratify the risk of mortality in addition to PAP.

Entities:  

Keywords:  DLCO; FVC; Mortality; Pulmonary hypertension

Mesh:

Year:  2016        PMID: 27888395     DOI: 10.1007/s11739-016-1573-9

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  28 in total

1.  Improved survival in limited scleroderma-related pulmonary artery hypertension.

Authors:  Carlo Marini; Bruno Formichi; Carolina Bauleo; Claudio Michelassi; Roberta Pancani; Renato Prediletto; Massimo Miniati; Giosuè Catapano; Simonetta Monti; Francesca Mannucci; Antonio Tavoni; Anna D'Ascanio; Luigi Emilio Pastormerlo; Alberto Giannoni; Carlo Giuntini
Journal:  Intern Emerg Med       Date:  2013-01-30       Impact factor: 3.397

2.  Severe pulmonary hypertension and chronic obstructive pulmonary disease.

Authors:  Ari Chaouat; Anne-Sophie Bugnet; Nabila Kadaoui; Roland Schott; Irina Enache; Alain Ducoloné; May Ehrhart; Romain Kessler; Emmanuel Weitzenblum
Journal:  Am J Respir Crit Care Med       Date:  2005-04-14       Impact factor: 21.405

Review 3.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

4.  Isolated diffusing capacity reduction in systemic sclerosis.

Authors:  V D Steen; G Graham; C Conte; G Owens; T A Medsger
Journal:  Arthritis Rheum       Date:  1992-07

5.  Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure.

Authors:  M Oswald-Mammosser; E Weitzenblum; E Quoix; G Moser; A Chaouat; C Charpentier; R Kessler
Journal:  Chest       Date:  1995-05       Impact factor: 9.410

6.  Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.

Authors:  N Galiè; Lj Rubin; Mm Hoeper; P Jansa; H Al-Hiti; Gmb Meyer; E Chiossi; A Kusic-Pajic; G Simonneau
Journal:  Lancet       Date:  2008-06-21       Impact factor: 79.321

Review 7.  Pulmonary hypertension. Anatomic and physiologic correlates.

Authors:  B Meyrick; L Reid
Journal:  Clin Chest Med       Date:  1983-05       Impact factor: 2.878

8.  Pulmonary function in primary pulmonary hypertension.

Authors:  Xing-Guo Sun; James E Hansen; Ronald J Oudiz; Karlman Wasserman
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

9.  Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis.

Authors:  Nadia Sivova; David Launay; Lidwine Wémeau-Stervinou; Pascal De Groote; Martine Remy-Jardin; Guillaume Denis; Marc Lambert; Nicolas Lamblin; Sandrine Morell-Dubois; Marie Fertin; Guillaume Lefevre; Vincent Sobanski; Olivier Le Rouzic; Pierre-Yves Hatron; Benoit Wallaert; Eric Hachulla; Thierry Perez
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

10.  Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.

Authors:  J Gerry Coghlan; Christopher P Denton; Ekkehard Grünig; Diana Bonderman; Oliver Distler; Dinesh Khanna; Ulf Müller-Ladner; Janet E Pope; Madelon C Vonk; Martin Doelberg; Harbajan Chadha-Boreham; Harald Heinzl; Daniel M Rosenberg; Vallerie V McLaughlin; James R Seibold
Journal:  Ann Rheum Dis       Date:  2013-05-18       Impact factor: 19.103

View more
  2 in total

1.  Incidence and Patterns of Interstitial Lung Disease and Their Clinical Impact on Mortality in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Korean Single-Centre Observational Study.

Authors:  Jang Woo Ha; Jung Yoon Pyo; Sung Soo Ahn; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  J Immunol Res       Date:  2022-05-23       Impact factor: 4.493

2.  Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization.

Authors:  Michele Correale; Ilenia Monaco; Armando Ferraretti; Lucia Tricarico; Monica Sicuranza; Anna Maria Gallotta; Ennio Sascia Formica; Gianfranco Acanfora; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Int J Cardiol Heart Vasc       Date:  2020-04-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.